What share issue did BioArctic (BIOA B) complete in May 2026?

In May 2026, BioArctic issued 5,000 new Class B shares. According to BioArctic, these shares were created through the exercise of 5,000 stock options from the 2019/2028 stock option program approved at the Annual General Meeting held on May 9, 2019.

When was the BioArctic (BIOA B) share and vote information last updated in May 2026?

The share and vote figures were stated as of May 29, 2026, the month’s last trading day. According to BioArctic, the information was released for public disclosure on May 29, 2026, at 6:30 pm CET under EU Market Abuse Regulation requirements.

Number of shares and votes in BioArctic AB (publ) as of May 29, 2026

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

BioArctic (Nasdaq Stockholm: BIOA B) issued 5,000 Class B shares in May 2026 through exercise of 5,000 stock options from the 2019/2028 program. As of May 29, 2026, BioArctic has 88,724,485 shares outstanding and 218,324,449 votes in total.

The share capital comprises 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. Each A share carries ten votes and each B share one vote.

Market Context

This announcement detailed a small issuance of 5,000 Class B shares from the 2019/2028 stock option ...

Analysis

This announcement detailed a small issuance of 5,000 Class B shares from the 2019/2028 stock option program, bringing total shares to 88,724,485, split between 74,324,489 listed Class B and 14,399,996 unlisted Class A shares. Voting power remains concentrated via ten votes per A share and one per B share, for a total of 218,324,449 votes. Investors may track how such option exercises and the existing S-3ASR shelf are used alongside prior AGM authorizations to shape future dilution and governance dynamics.

Key Figures

New shares issued: 5,000 Class B shares Options exercised: 5,000 stock options Total shares: 88,724,485 shares +5 more

8 metrics

New shares issued 5,000 Class B shares Issued in May 2026 via 2019/2028 stock option program

Options exercised 5,000 stock options Series 2019/2028 exercised to deliver shares

Total shares 88,724,485 shares Total outstanding as of May 29, 2026

Class B shares 74,324,489 shares Listed Class B shares as of May 29, 2026

Class A shares 14,399,996 shares Unlisted Class A shares as of May 29, 2026

Votes per A share 10 votes Voting power of each Class A share

Votes per B share 1 vote Voting power of each Class B share

Total votes 218,324,449 votes Aggregate voting rights in the company

Historical Context

5 past events · Latest: May 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 28	AGM and dividend	Positive	+0.6%	AGM approved 2025 accounts, SEK 2 dividend, and new issuance authorities.
May 22	Conference participation	Neutral	-0.8%	Announcement of participation in upcoming investor conferences and webcasts.
May 15	Partner revenue outlook	Positive	-5.6%	Eisai projected higher Leqembi revenue and related royalty income for BioArctic.
May 13	Earnings call invite	Neutral	+5.2%	Invitation to Q1 2026 report release and investor webcast with Q&A.
May 08	Q1 results & pipeline	Positive	+0.9%	Q1 2026 financials, positive Phase 1 data, follow-on offering and cash runway update.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News has generally aligned with price moves, with one notable divergence on positive Leqembi royalty guidance.

Recent Company History

Over recent months, BIOA combined corporate governance actions, pipeline progress, and financing. The AGM on May 28, 2026 approved a SEK 2 dividend and new issuance authority, with a modestly positive move. Positive Leqembi royalty projections on May 15, 2026 saw a -5.64% reaction, contrasting with the upbeat outlook. Earnings and clinical data on May 8, 2026 produced a small gain. Against this backdrop, the current minor share issuance for an option program fits ongoing capital structure adjustments.

Key Terms

stock option program, stock options, class b shares, class a shares, +1 more

5 terms

stock option program financial

"for delivery of shares to participants in the 2019/2028 stock option program resolved"

A stock option program is a company plan that gives employees or directors the right to buy company shares at a fixed price for a set period, similar to a coupon that lets you buy a product later at today’s price. It matters to investors because such programs can align staff incentives with company performance and help retain talent, but they also increase the number of shares over time, which can dilute existing ownership and affect earnings per share.

stock options financial

"The shares were issued through an exercise of 5,000 stock options of series 2019/2028."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

class b shares financial

"the company issued 5,000 Class B shares during May for delivery of shares"

Class B shares are one type of a company’s stock that carries a specific set of rights — often different voting power or dividend rules compared with other classes. For investors, that affects influence over company decisions and potential income: owning Class B might mean fewer or more votes per share or different claim on profits, like having a different seat at a decision table or a different slice of the payout pie.

class a shares financial

"14,399,996 unlisted Class A shares. The A share has ten votes per share"

Class A shares are one of a company’s distinct types of stock that come with a specific set of rights—commonly different voting power, dividend treatment, or transfer rules—defined in the company’s charter. Investors care because those rights affect control, income and resale value; like holding a seat at a table that has different rules or stronger chips than other seats, owning Class A changes how much influence and return you can expect.

eu market abuse regulation regulatory

"obliged to disclose pursuant to the EU Market Abuse Regulation."

A set of EU-wide rules that prevent cheating in financial markets by banning insider trading, market manipulation, and misleading disclosure; it also requires timely public release of key company information so everyone can play on a level field. For investors, it reduces the risk that prices are driven by secret deals or false signals, making markets fairer and more reliable for deciding when to buy or sell — like referees enforcing fair play in a game.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/30/2026 - 04:31 AM

STOCKHOLM, May 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 5,000 stock options of series 2019/2028.

As of May 29, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,724,485 shares, of which 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes in the company amounts to 218,324,449.

This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on May 29, 2026, at 6:30pm CET.

For further information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180

Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/number-of-shares-and-votes-in-bioarctic-ab--publ--as-of-may-29--2026,c4355174

The following files are available for download:

https://mb.cision.com/Main/9978/4355174/4122374.pdf

Number of shares and votes in
BioArctic AB (publ) as of May 29,
2026

View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-bioarctic-ab-publ-as-of-may-29-2026-302786236.html

SOURCE BioArctic

FAQ

How many BioArctic (BIOA B) shares were outstanding as of May 29, 2026?

As of May 29, 2026, BioArctic had 88,724,485 shares outstanding. According to BioArctic, this consists of 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares, reflecting the share capital after the May 2026 option exercises.

How many votes are attached to BioArctic (BIOA B) shares as of May 29, 2026?

BioArctic reported a total of 218,324,449 votes as of May 29, 2026. According to BioArctic, each Class A share carries ten votes and each Class B share one vote, creating a dual-class structure with differentiated voting power per share class.

How do BioArctic (BIOA B) Class A and Class B shares differ in voting rights?

BioArctic’s Class A shares have ten votes each, while Class B shares have one vote each. According to BioArctic, the company has 14,399,996 unlisted Class A shares and 74,324,489 listed Class B shares, together totaling 218,324,449 votes in the company.

What stock option program led to new BioArctic (BIOA B) shares in May 2026?

The May 2026 share issue came from the 2019/2028 stock option program. According to BioArctic, 5,000 options of series 2019/2028 were exercised, resulting in 5,000 newly issued Class B shares delivered to participants in that incentive program.